The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Data on KRAS inhibitors in lung cancer at WCLC 2022
Barbara Burtness, MD, Yale Cancer Center, New Haven, CT, talks on what she is most excited about at the IASLC 2022 World Conference on Lung Cancer congress, including data on cohorts of patients who have been treated with KRAS inhibitors including KRASG12C-mutant lung cancer. Dr Burtness is curious about data including on clinical predictors for response and molecular markers such as in co-mutations with STK11 and KEAP1 as well as on the impact on the immune system of KRASG12C inhibitors. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
